LCGC is signing collaborators from Pharma and Academia to a new Public-Private Partnering model by:

• Adding pharmaceutical compound libraries to our current 300,000-sample library

• Providing services at no cost in exchange for milestone-gated downstream compensation

• Alleviation of bottlenecks preventing academic researchers from successfully contributing to drug pipelines 

• Enhancing HTS efficiency by 5-fold or more to rapidly and cost-effectively detect drug candidates

• Making collaborations between industry and academic centers of excellence easier than ever

• Elevating success rates in pharmaceutical R&D with powerful six-sigma methodologies

For more information on Double-Blinded Drug Discovery, please see our Powerpoint presentation and brochure.

Copyright LCGC inc.